[go: up one dir, main page]

FI872917L - Farmaceutiska baerare, vilka frigoer aktivaemnet reglerbart. - Google Patents

Farmaceutiska baerare, vilka frigoer aktivaemnet reglerbart. Download PDF

Info

Publication number
FI872917L
FI872917L FI872917A FI872917A FI872917L FI 872917 L FI872917 L FI 872917L FI 872917 A FI872917 A FI 872917A FI 872917 A FI872917 A FI 872917A FI 872917 L FI872917 L FI 872917L
Authority
FI
Finland
Prior art keywords
reglerbart
frigoer
farmaceutiska
baerare
aktivaemnet
Prior art date
Application number
FI872917A
Other languages
English (en)
Other versions
FI87045B (fi
FI872917A0 (fi
FI87045C (fi
Inventor
Benjamin Oshlack
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25390936&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI872917(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of FI872917A0 publication Critical patent/FI872917A0/fi
Publication of FI872917L publication Critical patent/FI872917L/fi
Publication of FI87045B publication Critical patent/FI87045B/fi
Application granted granted Critical
Publication of FI87045C publication Critical patent/FI87045C/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FI872917A 1986-07-18 1987-07-01 Farmaceutiska baerare, vilka frigoer aktivaemnet reglerbart FI87045C (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88734086 1986-07-18
US06/887,340 US4861598A (en) 1986-07-18 1986-07-18 Controlled release bases for pharmaceuticals

Publications (4)

Publication Number Publication Date
FI872917A0 FI872917A0 (fi) 1987-07-01
FI872917L true FI872917L (fi) 1988-01-19
FI87045B FI87045B (fi) 1992-08-14
FI87045C FI87045C (fi) 1992-11-25

Family

ID=25390936

Family Applications (1)

Application Number Title Priority Date Filing Date
FI872917A FI87045C (fi) 1986-07-18 1987-07-01 Farmaceutiska baerare, vilka frigoer aktivaemnet reglerbart

Country Status (22)

Country Link
US (1) US4861598A (fi)
EP (1) EP0253104B1 (fi)
JP (2) JP2511054B2 (fi)
KR (1) KR930008954B1 (fi)
CN (1) CN1029770C (fi)
AT (1) ATE62404T1 (fi)
AU (1) AU596183B2 (fi)
CA (1) CA1296633C (fi)
DE (1) DE3769221D1 (fi)
DK (1) DK175627B1 (fi)
DZ (1) DZ1112A1 (fi)
EG (1) EG18574A (fi)
ES (1) ES2033259T3 (fi)
FI (1) FI87045C (fi)
GR (1) GR3001788T3 (fi)
IL (1) IL82604A (fi)
IN (1) IN166546B (fi)
MX (1) MX163284A (fi)
NO (1) NO169998C (fi)
NZ (1) NZ220406A (fi)
PT (1) PT85353B (fi)
ZA (1) ZA874038B (fi)

Families Citing this family (143)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4970075A (en) * 1986-07-18 1990-11-13 Euroceltique, S.A. Controlled release bases for pharmaceuticals
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5681585A (en) * 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5478577A (en) † 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5958459A (en) * 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
US20080075781A1 (en) * 1992-11-25 2008-03-27 Purdue Pharma Lp Controlled release oxycodone compositions
IL109460A (en) 1993-05-10 1998-03-10 Euro Celtique Sa Controlled release formulation comprising tramadol
US20070275062A1 (en) * 1993-06-18 2007-11-29 Benjamin Oshlack Controlled release oxycodone compositions
IL109944A (en) * 1993-07-01 1998-12-06 Euro Celtique Sa Continuous release dosage form containing morphine and a method of preparing such sustained release unit dosage forms
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US7740881B1 (en) 1993-07-01 2010-06-22 Purdue Pharma Lp Method of treating humans with opioid formulations having extended controlled release
US5879705A (en) * 1993-07-27 1999-03-09 Euro-Celtique S.A. Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
EP1442745A1 (en) * 1993-10-07 2004-08-04 Euro-Celtique Orally administrable opioid formulations having extended duration of effect
US5891471A (en) * 1993-11-23 1999-04-06 Euro-Celtique, S.A. Pharmaceutical multiparticulates
KR100354702B1 (ko) * 1993-11-23 2002-12-28 유로-셀티크 소시에떼 아노뉨 약학조성물의제조방법및서방형조성물
US5843480A (en) * 1994-03-14 1998-12-01 Euro-Celtique, S.A. Controlled release diamorphine formulation
US5430021A (en) * 1994-03-18 1995-07-04 Pharmavene, Inc. Hydrophobic drug delivery systems
US5484608A (en) * 1994-03-28 1996-01-16 Pharmavene, Inc. Sustained-release drug delivery system
ES2097087B1 (es) * 1994-08-01 1997-12-16 Univ Sevilla Sistema de liberacion controlada de morfina y otros farmacos solubles en agua por complejacion con sustancias polimericas.
GB9422154D0 (en) * 1994-11-03 1994-12-21 Euro Celtique Sa Pharmaceutical compositions and method of producing the same
US20020006438A1 (en) * 1998-09-25 2002-01-17 Benjamin Oshlack Sustained release hydromorphone formulations exhibiting bimodal characteristics
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
GB9519363D0 (en) 1995-09-22 1995-11-22 Euro Celtique Sa Pharmaceutical formulation
US5811126A (en) * 1995-10-02 1998-09-22 Euro-Celtique, S.A. Controlled release matrix for pharmaceuticals
JPH1050306A (ja) * 1996-07-31 1998-02-20 Toyota Autom Loom Works Ltd 水素吸蔵合金電極の製造方法
PT1041987E (pt) 1997-12-22 2006-07-31 Euro Celtique Sa Forma farmaceutica de dosagem oral, compreendendo uma combinacao de um agonista de opioide e naltrexona
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
AU5652199A (en) * 1998-09-18 2000-04-10 Takeda Chemical Industries Ltd. Sustained release oral preparations
US6806294B2 (en) 1998-10-15 2004-10-19 Euro-Celtique S.A. Opioid analgesic
DE19918325A1 (de) 1999-04-22 2000-10-26 Euro Celtique Sa Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
ES2374717T3 (es) * 1999-10-29 2012-02-21 Euro-Celtique S.A. Formulaciones de hidrocodona de liberación controlada.
EP2301542A1 (en) 2000-02-08 2011-03-30 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
US6716449B2 (en) 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
OA12215A (en) 2000-02-08 2006-05-09 Euro Celtique Sa Tamper-resistant oral opioid agonist formulations.
KR100968128B1 (ko) * 2000-10-30 2010-07-06 유로-셀티크 소시에떼 아노뉨 서방성 하이드로코돈 제형
US20110104214A1 (en) * 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
UA81224C2 (uk) * 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
ES2361148T3 (es) 2001-05-11 2011-06-14 Endo Pharmaceuticals Inc. Forma de dosificación de opioides de liberación controlada resistente al abuso.
AU2002316582B2 (en) * 2001-07-06 2007-03-15 Endo Pharmaceuticals, Inc. Oral administration of 6-hydroxy-oxymorphone for use as an analgesic
WO2003004033A1 (en) * 2001-07-06 2003-01-16 Penwest Pharmaceuticals Company Sustained release formulations of oxymorphone
US8329216B2 (en) * 2001-07-06 2012-12-11 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
WO2003007802A2 (en) 2001-07-18 2003-01-30 Euro-Celtique, S.A. Pharmaceutical combinations of oxycodone and naloxone
US20030157168A1 (en) 2001-08-06 2003-08-21 Christopher Breder Sequestered antagonist formulations
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
SI1414451T1 (sl) 2001-08-06 2009-10-31 Euro Celtique Sa Formulacije opioidnega agonista s sproščanja sposobnim in sekvestriranim antagonistom
CA2459976A1 (en) * 2001-09-26 2003-04-03 Penwest Pharmaceuticals Company Opioid formulations having reduced potential for abuse
EP1639997A1 (en) 2002-04-05 2006-03-29 Euro-Celtique S.A. Matrix for sustained, invariant and independant release of active compounds
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
US20050106249A1 (en) * 2002-04-29 2005-05-19 Stephen Hwang Once-a-day, oral, controlled-release, oxycodone dosage forms
RU2004134594A (ru) * 2002-04-29 2005-06-27 Алза Корпорейшн (Us) Способы и лекарственные формы для контролируемой доставки оксикодона
WO2003101384A2 (en) * 2002-05-31 2003-12-11 Alza Corporation Dosage forms and compositions for osmotic delivery of variable dosages of oxycodone
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
JP4694207B2 (ja) * 2002-07-05 2011-06-08 コルジウム ファーマシューティカル， インコーポレイテッド オピオイドおよび他の薬物に関する乱用抑止性の薬学的組成物
US8557291B2 (en) 2002-07-05 2013-10-15 Collegium Pharmaceutical, Inc. Abuse-deterrent pharmaceutical compositions of opioids and other drugs
US10004729B2 (en) 2002-07-05 2018-06-26 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
US8840928B2 (en) 2002-07-05 2014-09-23 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
US20050020613A1 (en) * 2002-09-20 2005-01-27 Alpharma, Inc. Sustained release opioid formulations and method of use
AU2003270778B2 (en) 2002-09-20 2009-10-08 Alpharma Pharmaceuticals, Llc Sequestering subunit and related compositions and methods
US20040110781A1 (en) * 2002-12-05 2004-06-10 Harmon Troy M. Pharmaceutical compositions containing indistinguishable drug components
CA2779723C (en) * 2002-12-13 2014-03-25 Durect Corporation Oral drug delivery system
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
MY135852A (en) 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
EP1479381A1 (en) * 2003-05-19 2004-11-24 Euro-Celtique S.A. Pharmaceutical dosage form comprising a solid solution
US20060165790A1 (en) * 2003-06-27 2006-07-27 Malcolm Walden Multiparticulates
TWI357815B (en) * 2003-06-27 2012-02-11 Euro Celtique Sa Multiparticulates
EP1663229B1 (en) 2003-09-25 2010-04-14 Euro-Celtique S.A. Pharmaceutical combinations of hydrocodone and naltrexone
US20050074493A1 (en) * 2003-10-03 2005-04-07 Mehta Atul M. Extended release formulations of opioids and method of use thereof
PL1691811T3 (pl) 2003-12-11 2014-12-31 Sunovion Pharmaceuticals Inc Skojarzenie leku uspokajającego i modulatora neuroprzekaźnikowego oraz sposoby poprawy jakości snu i leczenia depresji
TW201509943A (zh) 2004-03-30 2015-03-16 Euro Celtique Sa 含有小於２５ｐｐｍ１４-羥可待因酮之羥可酮鹽酸鹽之組成物、醫藥劑型、延遲釋出口服劑型及醫藥上可以接受的包裝
PL1729730T3 (pl) * 2004-03-30 2009-06-30 Euro Celtique Sa Odporna na zniszczenie postać dawkowania zawierająca adsorbent i środek przeciwdziałający
US20050226929A1 (en) * 2004-04-12 2005-10-13 Jianbo Xie Controlled release opioid analgesic formulation
US20050266082A1 (en) * 2004-05-26 2005-12-01 Patel Satishkumar A Preparation of stable paroxetine HC1 ER tablets using a melt granulation process
EP1604667A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the restless leg syndrome
EP1604666A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
DK1765292T3 (en) 2004-06-12 2018-01-02 Collegium Pharmaceutical Inc ABUSE PREVENTIONAL PHARMACEUTICAL FORMULATIONS
US9308164B2 (en) * 2004-06-30 2016-04-12 Sovereign Pharmaceuticals, Llc Hyoscyamine dosage form
GB2418854B (en) 2004-08-31 2009-12-23 Euro Celtique Sa Multiparticulates
PL2415484T3 (pl) * 2004-09-17 2014-11-28 Durect Corp Kompozycja znieczulająca miejscowo o przedłużonym uwalnianiu zawierająca SAIB
TWI369203B (en) 2004-11-22 2012-08-01 Euro Celtique Sa Methods for purifying trans-(-)-△9-tetrahydrocannabinol and trans-(+)-△9-tetrahydrocannabinol
BRPI0606339A2 (pt) * 2005-01-28 2009-06-16 Euro Celtique Sa formas farmacêuticas resistentes a álcool
EP1702558A1 (en) 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
EP1695700A1 (en) * 2005-02-28 2006-08-30 Euro-Celtique S.A. Dosage form containing oxycodone and naloxone
US20090214640A1 (en) * 2005-03-04 2009-08-27 Intelgenx Cporp. Delayed release pharmaceutical oral dosage form and method of making same
MY148074A (en) * 2005-05-10 2013-02-28 Novartis Ag Pharmaceutical compositions comprising imatinib and a release retardant
PT2168585E (pt) 2005-06-09 2012-03-05 Euro Celtique Sa Composições farmacêuticas de um esteróide neuroactivo e as suas utilizações
TWI366460B (en) 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
EP1896002A4 (en) 2005-06-27 2009-11-25 Biovail Lab Int Srl BUPROPIONAL SALT FORMULATIONS WITH MODIFIED RELEASE
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
EP1813276A1 (en) * 2006-01-27 2007-08-01 Euro-Celtique S.A. Tamper resistant dosage forms
US20070190141A1 (en) * 2006-02-16 2007-08-16 Aaron Dely Extended release opiate composition
US20070212414A1 (en) * 2006-03-08 2007-09-13 Penwest Pharmaceuticals Co. Ethanol-resistant sustained release formulations
US20070281016A1 (en) * 2006-06-06 2007-12-06 Endo Pharmaceuticals Inc., A Delaware Corporation Sustained release oxycodone composition with acrylic polymer and surfactant
US20070281017A1 (en) * 2006-06-06 2007-12-06 Endo Pharmaceuticals Inc., A Delaware Corporation Sustained release oxycodone composition with acrylic polymer and metal hydroxide
US20080069891A1 (en) 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
HUE032156T2 (en) 2006-06-19 2017-09-28 Alpharma Pharmaceuticals Llc Pharmaceutical preparations
US20080075768A1 (en) * 2006-07-21 2008-03-27 Vaughn Jason M Hydrophobic opioid abuse deterrent delivery system using opioid antagonists
BRPI0714484A2 (pt) * 2006-08-16 2013-04-24 Auspex Pharmaceuticals Inc composto, mÉtodo de tratar um mamÍfero sofrendo de uma doenÇa ou condiÇço, mÉtodo de tratar um memÍfero sofrendo de uma doenÇa, desordem, sintoma ou condiÇço e composiÇço farmacÊutica
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
DK2117521T3 (da) 2006-11-03 2012-09-03 Durect Corp Transdermale indgivelsessystemer omfattende bupivacain
US20080220064A1 (en) * 2006-12-06 2008-09-11 Ramesh Ketkar Anant Extended release matrix formulations of morphine
GB0624880D0 (en) * 2006-12-14 2007-01-24 Johnson Matthey Plc Improved method for making analgesics
US8202542B1 (en) 2007-05-31 2012-06-19 Tris Pharma Abuse resistant opioid drug-ion exchange resin complexes having hybrid coatings
US20090124650A1 (en) * 2007-06-21 2009-05-14 Endo Pharmaceuticals, Inc. Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instructions on Effects of Alcohol
AU2008335809A1 (en) * 2007-12-06 2009-06-18 Durect Corporation Methods useful for the treatment of pain, arthritic conditions, or inflammation associated with a chronic condition
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
US20090246276A1 (en) 2008-01-28 2009-10-01 Graham Jackson Pharmaceutical Compositions
US20100003322A1 (en) * 2008-07-03 2010-01-07 Lai Felix S Enteric coated hydrophobic matrix formulation
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
WO2010103039A1 (en) 2009-03-10 2010-09-16 Euro-Celtique S.A. Immediate release pharmaceutical compositions comprising oxycodone and naloxone
FR2946533A1 (fr) 2009-06-12 2010-12-17 Ethypharm Sa Reduction des fluctuations plasmatiques d'opioides.
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
WO2011143120A1 (en) 2010-05-11 2011-11-17 Cima Labs Inc. Alcoholres i stant metoprolol - containing extended - release oral dosage forms
CA2991217C (en) 2010-12-22 2020-06-09 Purdue Pharma L.P. Encased tamper resistant controlled release dosage forms
PH12013501345A1 (en) 2010-12-23 2022-10-24 Purdue Pharma Lp Tamper resistant solid oral dosage forms
US20130143867A1 (en) 2011-12-02 2013-06-06 Sychroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
EA201491875A1 (ru) 2012-04-17 2015-04-30 Пурдью Фарма Л.П. Системы и способы лечения индуцированного опиоидами побочного фармакодинамического ответа
EA028092B1 (ru) 2012-07-16 2017-10-31 Родс Текнолоджис Способ усовершенствованного синтеза опиоидов
MX362186B (es) 2012-07-16 2019-01-08 Rhodes Tech Proceso de sintesis de opioides mejorado.
EP2953618B1 (en) 2013-02-05 2020-11-11 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
CA2905131A1 (en) 2013-03-15 2014-09-18 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
EP3003297A4 (en) 2013-06-05 2017-04-19 Synchroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
MX2016000810A (es) 2013-07-23 2016-08-05 Euro Celtique Sa Combinacion de oxicodona y naloxona para su uso en el tratamiento de dolor en pacientes que sufren de dolor y una enfermedad que resulta la disbiosis intestinal y/o aumento del riesgo de la translocacion bacteriana intestinal.
WO2015015146A1 (en) 2013-08-02 2015-02-05 Johnson Matthey Public Limited Company Process for the preparation of oxymorphone
KR101868723B1 (ko) 2014-01-15 2018-06-18 로드스 테크놀로지즈 개선된 옥시코돈 합성을 위한 방법
CA2937007C (en) 2014-01-15 2018-11-06 Rhodes Technologies Process for improved oxymorphone synthesis
US9062063B1 (en) 2014-03-21 2015-06-23 Johnson Matthey Public Limited Company Forms of oxymorphone hydrochloride
US9849124B2 (en) 2014-10-17 2017-12-26 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response
US9918979B2 (en) 2015-01-29 2018-03-20 Johnson Matthey Public Limited Company Process of preparing low ABUK oxymorphone hydrochloride
US9943513B1 (en) 2015-10-07 2018-04-17 Banner Life Sciences Llc Opioid abuse deterrent dosage forms
CA3003950C (en) 2015-10-23 2020-05-12 Kashiv Pharma Llc Enhanced abuse-deterrent formulations of oxycodone
US10335405B1 (en) 2016-05-04 2019-07-02 Patheon Softgels, Inc. Non-burst releasing pharmaceutical composition
US9737530B1 (en) 2016-06-23 2017-08-22 Collegium Pharmaceutical, Inc. Process of making stable abuse-deterrent oral formulations
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
EP3645000A4 (en) 2017-06-30 2021-03-24 Purdue Pharma L.P. METHOD OF TREATMENT AND ITS DOSAGE FORMS
AU2018360383A1 (en) 2017-11-02 2020-05-21 Natureceuticals Sdn. Bhd. Extract of orthosiphon stamineus, formulations, and uses thereof
AU2018390826B2 (en) 2017-12-20 2024-09-12 Purdue Pharma L.P. Abuse deterrent morphine sulfate dosage forms
CN115666621A (zh) 2020-01-13 2023-01-31 度勒科特公司 具有减少的杂质的持续释放药物递送系统及相关方法
KR20230000634U (ko) 2021-09-16 2023-03-23 장상환 분리가능한 쇠스랑

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2805977A (en) * 1955-01-04 1957-09-10 Smith Kline French Lab Sustained release pharmaceutical preparation
GB1405088A (en) * 1971-06-03 1975-09-03 Mundipharma Ag Slow release formulation
US3965256A (en) * 1972-05-16 1976-06-22 Synergistics Slow release pharmaceutical compositions
SE418247B (sv) * 1975-11-17 1981-05-18 Haessle Ab Sett att framstella kroppar med reglerad frigoring av en aktiv komponent
SE7813246L (sv) * 1978-12-22 1980-06-23 Haessle Ab Fast farmaceutisk beredning innehallande kroppar med flera ytskikt
SE8003805L (sv) * 1980-05-21 1981-11-22 Haessle Ab En farmaceutisk beredning med forbettrade utlosningsegenskap
EP0064485B1 (en) * 1981-04-27 1985-07-24 Aktiebolaget Hässle New pharmaceutical preparation
DE3124983A1 (de) * 1981-06-25 1983-01-20 Meditest Inst Fuer Medizinisch Arzneiformen zur oralen verabreichung
US4443428A (en) * 1982-06-21 1984-04-17 Euroceltique, S.A. Extended action controlled release compositions
DK58983D0 (da) * 1983-02-11 1983-02-11 Leo Pharm Prod Ltd Farmaceutisk praeparat
JPS6143108A (ja) * 1984-08-03 1986-03-01 Nippon Shinyaku Co Ltd 医薬品製剤及びその製造法
NL8500724A (nl) * 1985-03-13 1986-10-01 Univ Groningen Inrichtingen voor geregelde afgifte van werkzame stoffen, alsmede werkwijze ter vervaardiging daarvan.

Also Published As

Publication number Publication date
ZA874038B (en) 1987-12-04
FI87045B (fi) 1992-08-14
AU7340387A (en) 1988-01-21
AU596183B2 (en) 1990-04-26
PT85353B (pt) 1990-04-30
IL82604A0 (en) 1987-11-30
JPH09136845A (ja) 1997-05-27
EP0253104A1 (en) 1988-01-20
CN1029770C (zh) 1995-09-20
MX163284A (es) 1992-04-03
DK367687D0 (da) 1987-07-15
KR930008954B1 (ko) 1993-09-17
FI872917A0 (fi) 1987-07-01
JP2511054B2 (ja) 1996-06-26
ATE62404T1 (de) 1991-04-15
CN87104429A (zh) 1988-01-27
NZ220406A (en) 1989-08-29
JPS6330427A (ja) 1988-02-09
DK175627B1 (da) 2004-12-27
CA1296633C (en) 1992-03-03
EP0253104B1 (en) 1991-04-10
FI87045C (fi) 1992-11-25
NO169998C (no) 1992-09-02
EG18574A (en) 1993-08-30
US4861598A (en) 1989-08-29
DE3769221D1 (de) 1991-05-16
IN166546B (fi) 1990-06-02
DZ1112A1 (fr) 2004-09-13
GR3001788T3 (en) 1992-11-23
IL82604A (en) 1990-08-31
ES2033259T3 (es) 1993-03-16
JP2661646B2 (ja) 1997-10-08
NO169998B (no) 1992-05-25
NO872989L (no) 1988-01-19
KR880001285A (ko) 1988-04-22
NO872989D0 (no) 1987-07-17
DK367687A (da) 1988-01-19
PT85353A (en) 1987-08-01

Similar Documents

Publication Publication Date Title
FI872917L (fi) Farmaceutiska baerare, vilka frigoer aktivaemnet reglerbart.
FI873584L (fi) Mjuk, sockerfri, poroes soetsaks- resp. bakverkssammansaettning.
FI875063L (fi) Syntetiskt, plasmafritt, transfusibelt foervaringsmedium foer blodplaettar.
FI873497L (fi) Foer direktlimning avsedd glasskiva, i synnerhet bilglas.
FI884892A0 (fi) Tippbar slaepvagn foer motorfordon, speciellt personbilar.
FI875022L (fi) Belysningsanordning foer fordon, saerskilt foer cykel.
FI874405L (fi) Avlaenkbart, flexibelt, elektriskt uppvaermningselement.
FI872630L (fi) Farmaceutiska kompositioner foer utvaertes bruk, vilka laett penetrerar huden.
FI872594L (fi) Cementprodukter, vilka innehaoller ytbehandlade oorganiska partiklar.
FI861110A0 (fi) Foerfarande foer framstaellning av en haerdad stenmaterialprodukt, isynnerhet betong.
FI881322L (fi) Haestsko, skaerskilt foer travhaestar.
FI872267L (fi) Stabila, vattenhaltiga suspensionskoncentratkompositioner.
FI874864A0 (fi) Oformade, eldfasta massor.
FI875092L (fi) Laminerat, textilbeklaett plastmaterial.
FI872598A0 (fi) N-1h-tetrazol-5-yl-2-tiofen-, n-1h -tetrazol-5-yl-2-pyrrol- och n-1h-tetrazol-5-yl-2-furankarboxamider.
FI865279A0 (fi) Profilbelagd foensterkonstruktion, i synnerhet foer bandfoenster.
FI871432A0 (fi) Foerkopplingsdrossel, speciellt foer gasurladdningslampor.
FI875128A0 (fi) Kabelmuff, isynnerhet en intagningskabelmuff foer partraods intagningskabel.
FI874479A (fi) Golvskoetselanordning, speciellt munstycke foer dammsugare.
FI862337A0 (fi) Spaenningsanordning foer en pappersmaskins vaevnader saosom viror, filtar, torkningsvaevnader, speciellt filtarna i presspartiet.
FI872660A0 (fi) Foerfarande foer framstaellning av metylenderivat av androst-4-en-3,17-dioner.
FI870924A (fi) Aromatiska -alkylimino-tetrahydro-6h -1,3-tiazin-6-onderivater.
FI872465L (fi) Vektorer, vilka innehaoller vaermechockreglerande dna-sekvenser.
FI883795A0 (fi) D,l-mantelsyra innehaollande haorvaordsmedel.
FI870544L (fi) Foerfarande foer framstaellning av o-alkyl-s,s-dialkylfosforditioater.

Legal Events

Date Code Title Description
FG Patent granted

Owner name: THE PURDUE PHARMA COMPANY

PC Transfer of assignment of patent

Owner name: MUNDIPHARMA OY

Free format text: MUNDIPHARMA OY

MA Patent expired